wtwco.com
19
Pharmacy evolution
© 2023 WTW. Proprietary and confidential. For WTW and WTW client use only.
How will employers need to respond?
• Cost transparency, plan design and formulary considerations
• Ensuring the appropriate clinical pathways are followed
• Explore specialty medication programs and channels, including maximizers (i.e., SaveOn, Prudent, Variable Copay, etc.),
and site of care options (i.e., medical vs Rx, home vs infusion, etc.)
Gene & Cell Therapies
Digital Therapeutics
Diabetes and Weight Loss
Biosimilar alternatives
Includes a deep pipeline with recent approvals launched
at record costs and will require new thinking around
payment models and delivery (i.e., pay overtime, pay for
performance)
Are currently being approved by the FDA and
prescribed by physicians (i.e., Mahana, Pear
Therapeutics, etc.)
In the pipeline to treat refractory depression, anxiety,
PTSD, etc., but will require additional provider visits in
addition to the drug cost
39 biosimilars approved and around 30 are on the market; launch
of highly anticipated autoimmune biosimilars in 2023
Psychedelics
Rapidly increasing utilization and significant cost for blockbuster
GLP-1 medications (Ozempic, Wegovy, Mounjaro, etc.) used for
diabetes treatment and weight loss; nearly $20,000/person/year